Search

Insmed

Uždarymo kaina

SektoriusSveikatos priežiūra

123.8 0.1

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

122.23

Max

125.95

Pagrindiniai rodikliai

By Trading Economics

Pajamos

150M

-13M

Pardavimai

120M

425M

Pelnas, tenkantis vienai akcijai

-0.52

Pelno marža

-3.112

Darbuotojai

1,664

EBITDA

150M

14M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+59.99% upside

Dividendai

By Acuity

Kitas uždarbis

2026-10-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

6.7B

28B

Ankstesnė atidarymo kaina

123.7

Ankstesnė uždarymo kaina

123.8

Naujienos nuotaikos

By Acuity

64%

36%

303 / 340 reitingas Healthcare

Insmed Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-24 19:56; UTC

Event
Social Media
News

Insmed Inc. received approval for Brinsupri in Japan, the first therapy for non-cystic fibrosis bronchiectasis. Shares are lower amid news of a major shareholder's stock sale.

2026-08-20 20:02; UTC

Insmed Inc shares are lower amid a significant decline in the Biotechnology sector. Trading volume is unusually high, with no specific news identified.

2026-08-19 23:41; UTC

Insmed Inc. shares are higher in after-market trading, reflecting notable volatility with significant fluctuations since Wednesday's close.

2026-08-17 20:02; UTC

Social Media
News

Insmed shares rise as Duquesne Capital reports $151.9 million stake and Mizuho sets a $192 price target amid ongoing product launches.

2026-08-14 19:36; UTC

Insmed Inc shares are lower, reflecting broader market sentiment after a reported decline in retail sales. The stock has closed lower for four consecutive sessions.

2026-08-13 19:51; UTC

News
Social Media

Insmed shares are lower despite raised earnings estimates and target price increases from HC Wainwright and Wells Fargo during Thursday's session.

2026-08-12 19:36; UTC

News

Insmed shares are trading lower despite multiple analysts issuing positive ratings and target price increases, including BMO's $192.00 and Cantor Fitzgerald's $235.00.

2026-08-11 21:16; UTC

Insmed Inc. shares moved slightly lower during after-market hours, remaining near the upper end of their one-month range and above the 20-day moving average.

2026-08-10 23:41; UTC

News

Analysts adjusted price targets for Insmed Inc. after recent evaluations. Shares are higher in after-market trading, reflecting positive sentiment amid these actions.

2026-08-07 21:21; UTC

Insmed Inc shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2026-08-06 23:56; UTC

Insmed Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

2026-08-05 23:22; UTC

Insmed Inc shares are higher in after-market trading, reflecting positive momentum amid a significant drop in crude oil prices and easing inflation concerns.

2026-08-03 19:16; UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

2026-07-31 20:06; UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

2026-07-30 21:16; UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

2026-07-28 19:26; UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

2026-07-27 23:41; UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

2026-07-24 23:46; UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

2026-07-22 19:11; UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

2026-07-21 17:41; UTC

Social Media
News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

2026-07-20 19:16; UTC

News
Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Akcijų palyginimas

Kainos pokytis

Insmed Prognozė

Kainos tikslas

By TipRanks

59.99% į viršų

12 mėnesių prognozė

Vidutinis 201.22 USD  59.99%

Aukščiausias 243 USD

Žemiausias 169 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Insmed kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

19

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

303 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
help-icon Live chat